UCB SA (OTCMKTS:UCBJY) Sees Large Increase in Short Interest

UCB SA (OTCMKTS:UCBJY) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 2,600 shares, a growth of 1,200.0% from the March 31st total of 200 shares. Based on an average daily volume of 24,200 shares, the days-to-cover ratio is currently 0.1 days.

UCB Stock Performance

UCBJY stock opened at $67.30 on Friday. UCB has a 52-week low of $34.85 and a 52-week high of $67.30. The stock’s fifty day simple moving average is $59.36 and its 200-day simple moving average is $47.89.

UCB Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 29th will be issued a dividend of $0.4574 per share. This represents a dividend yield of 0.71%. The ex-dividend date of this dividend is Friday, April 26th. UCB’s dividend payout ratio (DPR) is 46.55%.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.